The phrase "game changer" in the context of prostate cancer seems like a bold claim, but at least one analyst sees that degree of potential for one of Endocyte Inc.'s pipeline candidates. But first, consider the West Lafayette, Ind.-based firm's chimeric antigen receptor T-cell (CAR T) effort, which drew attention at the American Association for Cancer Research (AACR) meeting last month in Chicago.